Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001493152-26-028655

← back to feed
Filed
Jun 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Jun 15, 2026 4.52M sh
Shares Diluted Q2 2026 · Apr 30, 2026 4.52M sh
Shares Diluted Q2 2026 · Apr 30, 2026 4.49M sh
Shares Diluted Q2 2026 · Apr 30, 2025 4.46M sh
Shares Diluted Q2 2026 · Apr 30, 2025 4.46M sh
Capex Q2 2026 · Apr 30, 2026 $33.81K
Operating Cash Flow Q2 2026 · Apr 30, 2026 −$1.54M
Operating Cash Flow Q2 2026 · Apr 30, 2025 −$1.12M
Long Term Debt Q2 2026 · Apr 30, 2026 $3.29M
Long Term Debt Q2 2026 · Oct 31, 2025 $8.99M
Short Term Debt Q2 2026 · Apr 30, 2026 $6.72M
Short Term Debt Q2 2026 · Oct 31, 2025 $593.75K
Stockholders Equity Q2 2026 · Apr 30, 2026 −$16.53M
Stockholders Equity Q2 2026 · Jan 31, 2026 −$16.15M
Stockholders Equity Q2 2026 · Oct 31, 2025 −$16.33M
Stockholders Equity Q2 2026 · Apr 30, 2025 −$11.07M
Stockholders Equity Q2 2026 · Jan 31, 2025 −$9.91M
Stockholders Equity Q2 2026 · Oct 31, 2024 −$9M
Current Liabilities Q2 2026 · Apr 30, 2026 $16.63M
Current Liabilities Q2 2026 · Oct 31, 2025 $5.68M
Total Liabilities Q2 2026 · Apr 30, 2026 $20.91M
Total Liabilities Q2 2026 · Oct 31, 2025 $21.26M
Current Assets Q2 2026 · Apr 30, 2026 $364.05K
Current Assets Q2 2026 · Oct 31, 2025 $862.1K
Total Assets Q2 2026 · Apr 30, 2026 $4.37M
Total Assets Q2 2026 · Oct 31, 2025 $4.93M
Eps Diluted Q2 2026 · Apr 30, 2026 −$0.35
Eps Diluted Q2 2026 · Apr 30, 2026 −$0.61
Eps Diluted Q2 2026 · Apr 30, 2025 −$0.33
Eps Diluted Q2 2026 · Apr 30, 2025 −$0.97
Eps Basic Q2 2026 · Apr 30, 2026 −$0.35
Eps Basic Q2 2026 · Apr 30, 2026 −$0.61
Eps Basic Q2 2026 · Apr 30, 2025 −$0.33
Eps Basic Q2 2026 · Apr 30, 2025 −$0.97
Sga Expense Q2 2026 · Apr 30, 2026 $1.4M
Sga Expense Q2 2026 · Apr 30, 2026 $2.74M
Sga Expense Q2 2026 · Apr 30, 2025 $1.24M
Sga Expense Q2 2026 · Apr 30, 2025 $3.37M
Rd Expense Q2 2026 · Apr 30, 2026 $109.81K
Rd Expense Q2 2026 · Apr 30, 2026 $279.03K
Rd Expense Q2 2026 · Apr 30, 2025 $222.43K
Rd Expense Q2 2026 · Apr 30, 2025 $296.31K
Net Income Q2 2026 · Apr 30, 2026 −$1.55M
Net Income Q2 2026 · Apr 30, 2026 −$2.66M
Net Income Q2 2026 · Jan 31, 2026 −$1.11M
Net Income Q2 2026 · Apr 30, 2025 −$1.48M
Net Income Q2 2026 · Apr 30, 2025 −$4.31M
Net Income Q2 2026 · Jan 31, 2025 −$2.83M
Operating Income Q2 2026 · Apr 30, 2026 −$1.17M
Operating Income Q2 2026 · Apr 30, 2026 −$2.36M
Operating Income Q2 2026 · Apr 30, 2025 −$1.08M
Operating Income Q2 2026 · Apr 30, 2025 −$2.93M
Gross Profit Q2 2026 · Apr 30, 2026 $342.5K
Gross Profit Q2 2026 · Apr 30, 2026 $754.45K
Gross Profit Q2 2026 · Apr 30, 2025 $376.76K
Gross Profit Q2 2026 · Apr 30, 2025 $733.54K
Cost Of Revenue Q2 2026 · Apr 30, 2026 $103.8K
Cost Of Revenue Q2 2026 · Apr 30, 2026 $221.26K
Cost Of Revenue Q2 2026 · Apr 30, 2025 $134.83K
Cost Of Revenue Q2 2026 · Apr 30, 2025 $227.92K
Revenue Q2 2026 · Apr 30, 2026 $446.3K
Revenue Q2 2026 · Apr 30, 2026 $975.71K
Revenue Q2 2026 · Apr 30, 2025 $511.58K
Revenue Q2 2026 · Apr 30, 2025 $961.46K